Latest News

Keep up to date with the latest news from Pilatus Biosciences.

News

April 8, 2026

Pilatus Biosciences to Present New Data Highlighting Sex-Specific Efficacy of CD36-Targeting Antibody in Colorectal Cancer at AACR 2026

March 12, 2026

Pilatus Biosciences Announces First Patient Dosed in Phase 1 Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors

February 19, 2026

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

December 15, 2025

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors

Upcoming Events

Currently, there are no scheduled upcoming events.